Evaluation of the the metabolic syndrome criteria and body composition in ambulatory children with Epilepsy in southern Iran: a case – control study
Iranian Journal of Child Neurology,
Vol. 14 No. 3 (2020),
1 July 2020
,
Page 47-56
https://doi.org/10.22037/ijcn.v14i3.23655
Abstract
Objectives: Previous studies in adults with epilepsy revealed a higher prevalence of metabolic syndrome, which resulted in cerebrovascular and cardiovascular events, however, there is insufficient data about body composition and metabolic syndrome in children, especially in Middle Eastern region. We aim to Investigate metabolic syndrome criteria and body composition in ambulatory children with Epilepsy in Southern Iran.
Material and Methods: 90 children aged 11.4 ± 3.2 years with epilepsy and their age- gender-matched controls were included in this study. Anthropometric data, lipid profile, blood sugar and blood pressure were checked. Body composition was evaluated using Hologic system dual – energy X-ray absorptiometry.
Results: Prevalence of metabolic syndrome in patients (6.7%) was more than the controls (1.1%) (p-value = 0.043). Patients’ fat mass index was more than the controls (P = 0.012), and lean mass+ Bone Mineral Content (BMC) index lower than the controls (P = 0.017). Serum triglycerides in patients using carbamazepine was higher than the others (P = 0.019, Beta = 0.379). Blood pressure was higher in patients using carbamazepine (p = 0.016, Beta = -0.26). Fat mass index was higher in patients using sodium valproate (p = 0.031, Beta = 0.238).
Conclusion: Our study revealed that children with epilepsy are more prone to metabolic syndrome and higher body fat mass. Therefore, early diagnosis and prevention of metabolic syndrome criteria in patients with epilepsy, performing regular exercise and having a healthy diet should be encouraged in these children.
- Body Composition
- Children
- Epilepsy
- Metabolic
How to Cite
References
Ahrens W, Moreno LA, Marild S, et al. Metabolic syndrome in young children: definitions and results of the IDEFICS study. Int J Obes (Lond). 2014;38:S4-14.
Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-80.
-Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 [published correction appears in Lancet. 2014 Aug 30;384(9945):746]. Lancet. 2014;384(9945):766-781
Ahmadi A, Gharipour M, Nouri F, et al. Metabolic syndrome in Iranian youths: a population-based study on junior and high schools students in rural and urban areas. J Diabetes Res. 2013;2013:738485.
Wang B, Liu Y, He P, et al. Prevalence of metabolic syndrome in an elderly Chinese population: a community-based cross-sectional study. J Am Geriatr Soc. 2010;58:2027-8.
Rakitin A, Koks S, Haldre S. Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine. Seizure. 2016;38:11-6.
Nair SS, Harikrishnan S, Sarma PS, et al. Metabolic syndrome in young adults with epilepsy. Seizure. 2016;37:61-4.
Verrotti A, Manco R, Agostinelli S, et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia. 2010;51:268-73.
Rakitin A, Eglit T, Koks S, et al. Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia. PLoS One. 2014;9:e103856.
Fang J, Chen S, Tong N, et al. Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate. Seizure. 2012;21:578-82.
Belcastro V, D'Egidio C, Striano P, et al Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013;107:1-8.
Dhir A, Sharma S, Jain P, et al. Parameters of metabolic syndrome in Indian children with epilepsy on valproate or phenytoin monotherapy. J Pediatr Neurosci. 2015;10:222-6.
Marshall WA. Growth and sexual maturation in normal puberty. Clin Endocrinol Metab. 1975;4:3-25.
14. Fong CY, Kong AN, Noordin M, Poh BK, Ong LC, Ng CC. Determinants of low bone mineral density in children with epilepsy. Eur J Paediatr Neurol. 2018;22(1):155-163
Zemel BS, Kalkwarf HJ, Gilsanz V, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab. 2011;96:3160-9.
De Lorenzo A, Soldati L, Sarlo F, Calvani M, Di Lorenzo N, Di Renzo L. New obesity classification criteria as a tool for bariatric surgery indication. World J Gastroenterol. 2016;22(2):681-70317.Zimmet P, Alberti KG, Kaufman F, et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. 2007;8:299-306.
Ben-Menachem E. Weight issues for people with epilepsy--a review. Epilepsia. 2007;48 Suppl 9:42-5.
Steinhoff BJ, Neususs K, Thegeder H, et al. Leisure time activity and physical fitness in patients with epilepsy. Epilepsia. 1996;37:1221-7.
Moses L, Katz N, Weizman A. Impact of epilepsy and antiepileptic medications on the metabolic profile in adults with autism spectrum disorder and intellectual disabilities. Int Clin Psychopharmacol. 2015;30:351-5.
Ciszowski K, Szpak D, Jenner B. The influence of carbamazepine plasma level on blood pressure and some ECG parameters in patients with acute intoxication. Przegl Lek. 2007;64:248-51.
Akamine Y, Uehara H, Miura M, et al. Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine. J Clin Pharm Ther. 2015;40:480-2.
Rauchenzauner M, Griesmacher A, Tatarczyk T, et al. Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children. Dev Med Child Neurol. 2010;52:283-8.
Lakhanpal D, Kaur G. Valproic acid alters GnRH-GABA interactions in cycling female rats. Cell Mol Neurobiol. 2007;27:1069-83.
Biton V, Levisohn P, Hoyler S, et al. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol. 2003;18:133-9.
Brown R, Imran SA, Ur E, et al. Valproic acid and CEBPalpha-mediated regulation of adipokine gene expression in hypothalamic neurons and 3T3-L1 adipocytes. Neuroendocrinology. 2008;88:25-34.
Greco R, Latini G, Chiarelli F, et al. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology. 2005;65:1808-9.
Hamed SA, Fida NM, Hamed EA. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. Eur J Paediatr Neurol. 2009;13:261-8.
Prodam F, Bellone S, Casara G, et al. Ghrelin levels are reduced in prepubertal epileptic children under treatment with carbamazepine or valproic acid. Epilepsia. 2010;51:312-5.
Gungor S, Yucel G, Akinci A, et al. The role of ghrelin in weight gain and growth in epileptic children using valproate. J Child Neurol. 2007;22:1384-8.
- Abstract Viewed: 205 times